Skip to content

Study on the Safety and efficacy of inhalable reduction therapy in the prevention and treatment of postoperative delirium in Elderly Patients with Hip fractures

Study on the Safety and efficacy of inhalable reduction therapy in the prevention and treatment of postoperative delirium in Elderly Patients with Hip fractures

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600120799
Enrollment
Unknown
Registered
2026-03-19
Start date
2026-03-19
Completion date
Unknown
Last updated
2026-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hip fracture, Delirium

Interventions

Experimental group:Inhalation of hydrogen-oxygen mixed gas

Sponsors

Peking University Shenzhen Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Age >=60 years old, gender not limited; 2.Meet the diagnostic criteria for hip fractures (refer to the "Guidelines for the Diagnosis, Treatment and Management of Hip Fractures in the Elderly (2022 Edition)"); 3.Surgical treatment is required; 4.The patient agreed to join this clinical study, voluntarily signed the informed consent form, and agreed to participate in all visits, examinations and treatments as required by the research protocol;

Exclusion criteria

Exclusion criteria: 1.Accompanied by fractures in other parts; 2.Patients with severe primary diseases such as cardiovascular and cerebrovascular, urinary and hematopoietic system diseases, malignant tumors, other serious comorbidities or mental illness; 3.Anti-delirium drugs were used before and after the operation; 4.Mentally or legally disabled, unable to communicate or cooperate normally with researchers; 5.The patient was transferred to another department for various reasons and was unable to complete all the interventions; 6.Those who are known to be intolerant to inhalation therapy;

Design outcomes

Primary

MeasureTime frame
Confusion Assessment Method,CAM;

Secondary

MeasureTime frame
Medication situation;Height;Blood routine;Weight;Pittsburgh Sleep Quality Index,PSQI;Inflammatory factors;Age;Liver function test;Educational attainment;The incidence of adverse events within 30 days after discharge;Body Mass Index;Numeric Rating Sale,NRS;Marital status;Complications;Residence mode;Blood pressure;Renal function examination;Heart rate;Sex;Occupation;Coagulation function;

Countries

China

Contacts

Public ContactLiu Pei

Peking University Shenzhen Hospital

szzjia@126.com+86 13500053715

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 3, 2026